BALAXINSEBALAXI PHARMACEUTICALS LIMITEDMediumNeutral
Announced Wed, 25 Mar · 13:10 IST

BALAXI PHARMACEUTICALS LIMITED has informed the Exchange about Change in Company Secretary/Compliance Officer

Management Changes View source PDF

BALAXI · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-5.9%1-day move
₹18.06
prior close
₹17.86
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.1+0.7-0.2-0.2-5.9-12.5+4.1+15.7+21.8+32.4+53.5+46.7+41.6+29.0
Up moveDown movePending
AI summary

Balaxi Pharmaceuticals has appointed Mr. Aman Purohit as its new Company Secretary and Compliance Officer, effective March 25, 2026, following a board meeting held on the same day. Mr. Purohit is an Associate Member of ICSI (membership number A59345) and holds a B.Com (Honours) in Accountancy from the University of Calcutta. He brings 6 years of post-qualification experience in secretarial compliance, mergers & acquisitions, corporate restructuring, due diligence, fund-raising and strike-off matters, with prior stints at Patil Rail Infrastructure Pvt Ltd and Re Sustainability IWM Solutions Ltd. The appointment was made on the recommendation of the Nomination and Remuneration Committee.

Likely market impact

This is a routine key managerial personnel (KMP) change at the compliance level and is unlikely to have a material impact on the stock price or business operations. Shareholders should note that the company now has a fully appointed Company Secretary, which is a regulatory requirement under the Companies Act.